Anticancer agent containing dendritic cell having RNA virus transferred thereinto
AssigneeDNA VEC Research Inc.
InventorsShinji Okano, Yoshikazu Yonemitsu, Katsuo Sueishi, Satoko Shibata, Mamoru Hasegawa, Haruhiko Kondo
Life of this patent
Estimating the term…
Abstract
The present invention provides anticancer agents comprising dendritic cells introduced with RNA viruses. The present invention also provides methods for producing anticancer agents, which comprise the step of preparing dendritic cells introduced with RNA viruses. The present invention also provides methods for treating cancers using dendritic cells introduced with RNA viruses. The present invention provides effective methods for treating cancers, which use RNA viruses and dendritic cells in combination.
Claims18
A method for producing an anticancer agent, which comprises:
- introducing a Sendai virus Z strain able to replicate its genome into a CD11c+immature dendritic cell, wherein said genome of the Sendai virus undergoes replication in the dendritic cell, thereby inducing maturation of said dendritic cell, and
- formulating the anticancer agent comprising the dendritic cell containing the virus and a pharmaceutical acceptable carrier or media.
A method for suppressing a cancer, which comprises:
- introducing a Sendai virus Z strain able to replicate its genome into a CD11c+ immature dendritic cell, wherein said genome of the Sendai virus undergoes replication in the dendritic cell, thereby inducing maturation of said dendritic cell, and
- administering to a subject having a cancer the dendritic cell containing the virus able to replicate its genome.
Dependencies are inferred from the claim text.